{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for tyrosine in Any Name (approximate match)
Status:
Investigational
Source:
NCT03374943: Phase 1 Interventional Completed Glioblastoma
(2017)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT01996267: Phase 3 Interventional Active, not recruiting Breast Cancer
(2013)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT01472016: Phase 1 Interventional Completed Advanced Solid Tumors
(2011)
Source URL:
Class:
PROTEIN
Status:
Class:
PROTEIN
Status:
Investigational
Source:
NCT01918254: Phase 1 Interventional Completed Breast Cancer
(2013)
Source URL:
Class:
PROTEIN
Class:
PROTEIN
Status:
Investigational
Source:
NCT01100736: Early Phase 1 Interventional Completed Pulmonary Arterial Hypertension
(2009)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02213289: Phase 2 Interventional Completed Adenocarcinoma
(2015)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03427151: Phase 3 Interventional Completed Lupus Erythematosus, Systemic
(2018)
Source URL:
Class:
PROTEIN
Forigerimod (also known as IPP-201101) a phosphopeptide is being investigated for the treatment of Lupus Erythematosus, Systemic. This drug is completed phase III clinical trials and is ready for licensing.
Status:
Investigational
Source:
NCT00785408: Phase 2 Interventional Completed Obesity
(2008)
Source URL:
Class:
PROTEIN
Davalintide (AC-2307) is a second-generation mimetic of a pancreatic peptide hormone amylin, developed by Amylin Pharmaceuticals. In preclinical models, davalintide possessed enhanced pharmacological properties and was able to reduce food intake. Safety, tolerability, and effect on body weight of subcutaneous davalintide were investigated in obese or overweight subjects. The results of the clinical trial were not reported, but Amylin decided to discontinue davalintide in 2010.
